SCHEMBL2842886

SCHEMBL2842886

C[C@H](N)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020014 1.00
SCHEMBL2836152 1.00
SCHEMBL6853792 0.97 EPHX1 (0.43)
SCHEMBL22191947 0.97 EPHX1 (0.43)
SCHEMBL56860 0.97
Hydrochloric Acid SCHEMBL15663093 0.97
Hydrochloric Acid SCHEMBL1984857 0.97
SCHEMBL22606844 0.97 EPHX1 (0.43)
SCHEMBL3052722 0.97 EPHX1 (0.43)
SCHEMBL55861 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780875-B2 RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS SMITHKLINE BEECHAM S.P.A. (IT) 2004-08-24 US claimed
CN-111518166-B Peptidomimetics compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 中国药科大学 2023-01-31 CN disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20160023198-A1 Metallorganocatalysis For Asymmetric Transformations Rutgars, The State University of New Jersey (US) 2016-01-28 US disclosed
US-8742106-B2 Disubstituted heteroaryl-fused pyridines NOVARTIS AG (CH) 2014-06-03 US disclosed
US-8742106-B2 Disubstituted heteroaryl-fused pyridines NOVARTIS AG (CH) 2014-06-03 US disclosed
EP-2516437-B1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2014-01-29 EP disclosed
US-20120258973-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2012-10-11 US disclosed
US-20120258973-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2012-10-11 US disclosed
WO-2011076744-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES NOVARTIS AG (CH) 2011-06-30 WO disclosed
US-7851642-B2 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound NOVARTIS AG (CH) 2010-12-14 US disclosed
US-20090253701-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253703-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-10-08 US disclosed
US-7582782-B2 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers NOVARTIS AG (CH) 2009-09-01 US disclosed
US-20070135498-A1 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers NOVARTIS AG (CH) 2007-06-14 US disclosed
EP-1689702-A1 ORGANIC COMPOUNDS NOVARTIS-PHARMA GMBH (AT) 2006-08-16 EP disclosed
WO-2005051895-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-06-09 WO disclosed
US-6780875-B2 RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS SMITHKLINE BEECHAM S.P.A. (IT) 2004-08-24 US disclosed
WO-1994002441-A1 A PROCESS FOR MAKING 1-CYCLOPENTYLALKYL AMINES USEFUL FOR THE SYNTHESIS OF SWEETENERS THE COCA-COLA COMPANY (US) 1994-02-03 WO disclosed
US-5225591-A One-step reduction of an azanorbornene THE COCA-COLA COMPANY (US) 1993-07-06 US disclosed